

NALP12 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP7281b**Specification**

NALP12 Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [P59046](#)**NALP12 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 91662**Other Names**

NACHT, LRR and PYD domains-containing protein 12, Monarch-1, PYRIN-containing APAF1-like protein 7, Regulated by nitric oxide, NLRP12, NALP12, PYPAF7, RNO

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7281b](/product/products/AP7281b) was selected from the C-term region of human NALP12. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

NALP12 Antibody (C-term) Blocking Peptide - Protein Information**Name** NLRP12**Synonyms** NALP12, PYPAF7, RNO**Function**

Plays an essential role as an potent mitigator of inflammation (PubMed: [30559449](http://www.uniprot.org/citations/30559449)). Primarily expressed in dendritic cells and macrophages, inhibits both canonical and non-canonical NF-kappa-B and ERK activation pathways (PubMed: [15489334](http://www.uniprot.org/citations/15489334), PubMed: [17947705](http://www.uniprot.org/citations/17947705)). Functions as a negative regulator of NOD2 by targeting it to degradation via the proteasome pathway (PubMed: [30559449](http://www.uniprot.org/citations/30559449)). In turn, promotes bacterial tolerance (PubMed: [30559449](http://www.uniprot.org/citations/30559449)).

[30559449](http://www.uniprot.org/citations/30559449)). Inhibits also the RIGI- mediated immune signaling against RNA viruses by reducing the E3 ubiquitin ligase TRIM25-mediated 'Lys-63'-linked RIGI activation but enhancing the E3 ubiquitin ligase RNF125-mediated 'Lys-48'-linked RIGI degradation (PubMed:[30902577](http://www.uniprot.org/citations/30902577)). Acts also as a negative regulator of inflammatory response to mitigate obesity and obesity-associated diseases in adipose tissue (By similarity).

Cellular Location

Cytoplasm.

Tissue Location

Detected only in peripheral blood leukocytes, predominantly in eosinophils and granulocytes, and at lower levels in monocytes.

NALP12 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

NALP12 Antibody (C-term) Blocking Peptide - Images**NALP12 Antibody (C-term) Blocking Peptide - Background**

NALPs are cytoplasmic proteins that form a subfamily within the larger CATERPILLER protein family. Most short NALPs, such as NALP12, have an N-terminal pyrin (MEFV; MIM 608107) domain (PYD), followed by a NACHT domain, a NACHT-associated domain (NAD), and a C-terminal leucine-rich repeat (LRR) region. The long NALP, NALP1 (MIM 606636), also has a C-terminal extension containing a function to find domain (FIIND) and a caspase recruitment domain (CARD). NALPs are implicated in the activation of proinflammatory caspases (e.g., CASP1; MIM 147678) via their involvement in multiprotein complexes called inflammasomes.

NALP12 Antibody (C-term) Blocking Peptide - References

Ye,Z., Mol. Cell. Biol. 28 (5), 1841-1850 (2008)Jeru,I., Proc. Natl. Acad. Sci. U.S.A. 105 (5), 1614-1619 (2008)Arthur,J.C., J. Immunol. 179 (9), 6291-6296 (2007)